Formulation Development and Evaluation of Flunarizine HCl Tablet by using Tablet in Tablet Technique

The present research focuses on developing a tablet-in-tablet dosage form containing Flunarizine HCl to provide both immediate and sustained drug release in a single unit. Flunarizine HCl is a poorly water-soluble drug primarily used for migraine treatment. In this study, the inner core tablet was designed for sustained release using HPMC K4M and Eudragit RS 100, while the outer shell was designed for immediate release using Crospovidone and MCC. The effects of important excipients on drug release and assay were investigated in order to optimize the formulation using a 2² factorial approach. Pre- and post-compression properties such as strength, thickness, flexibility, moisture level, FTIR compatibility, DSC thermograms, and the formulations' in vitro drug release were evaluated. batch that was optimized had favourable physical characteristics, consistent drug content, and appropriate release profiles. According to the study's findings, the tablet-in-tablet method shows promise in producing modulated release and enhancing patient adherence for long-term illnesses like migraines.